Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.

Garg, Scot; Chichareon, Ply; Kogame, Norihiro; Takahashi, Kuniaki; Modolo, Rodrigo; Chang, Chun-Chin; Tomaniak, Mariusz; Fath-Ordoubadi, Farzin; Anderson, Richard; Oldroyd, Keith G; Stables, Rod H; Kukreja, Neville; Chowdhary, Saqib; Galasko, Gavin; Hoole, Stephen; Zaman, Azfar; Hamm, Christian W; Steg, Philippe G; Jüni, Peter; Valgimigli, Marco; ... (2020). Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and cardiovascular interventions, 96(7), pp. 1369-1378. Wiley-Blackwell 10.1002/ccd.28649

[img] Text
Impact of established cardiovascular disease on outcomes.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

OBJECTIVE

To investigate the impact of different anti-platelet strategies on outcomes after percutaneous coronary intervention (PCI) in patients with established cardiovascular disease (CVD).

METHODS

GLOBAL LEADERS was a randomized, superiority, all-comers trial comparing one-month dual anti-platelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy (experimental treatment) with standard 12-month DAPT followed by 12-month aspirin monotherapy (reference treatment) in patients treated with a biolimus A9-eluting stent. Established CVD was defined as ≥1 prior myocardial infarction, PCI, coronary artery bypass operation, stroke, or established peripheral vascular disease. The primary endpoint was a composite of all-cause death or new Q-wave MI at 2-years. The secondary safety endpoint was BARC 3 or 5 bleeding. Exploratory secondary endpoints were the patient-orientated composite endpoint and net adverse clinical events.

RESULTS

Among the 15,761 patients in this cohort were 6,693 patients (42.5%) with established CVD. Compared to those without established CVD, these patients had significantly higher rates of the primary (5.1 vs. 3.3%, HR1.59[1.36-1.86], p < .001) and secondary composite endpoints with no significant differences in bleeding. There was a nonsignificant reduction in the primary endpoint in patients with established CVD receiving the experimental treatment (4.6 vs. 5.6%, HR0.82[0.66-1.02], p = .07). When comparing patients without CVD to those with one or three territories of CVD, the hazard ratio for the primary endpoint increased in unadjusted and adjusted models.

CONCLUSIONS

The poorer outcomes in patients with established CVD are not mitigated by prolonged monotherapy with a potent P2Y12 inhibitor suggesting a greater need to focus on modifiable risk factors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Valgimigli, Marco and Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-1946

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

07 Feb 2020 14:55

Last Modified:

13 Dec 2020 01:30

Publisher DOI:

10.1002/ccd.28649

PubMed ID:

31854112

Uncontrolled Keywords:

antiplatelet cardiovascular disease coronary artery disease percutaneous coronary intervention poly-vascular disease

BORIS DOI:

10.7892/boris.139034

URI:

https://boris.unibe.ch/id/eprint/139034

Actions (login required)

Edit item Edit item
Provide Feedback